Eli Lilly & Co. (LLY) option IV bid into end of year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Citi Reiterates Buy Rating on Eli Lilly (LLY)
December 20, 2024 8:43 AM ESTCiti analyst Geoff Meacham reiterated a Buy rating and $1,250.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "We expect LLY shares to be strong today on the announcement of competitor Novos (not covered) phase 3 REDEFINE-1 study of CagriSema for obesity.... More
